Literature DB >> 20729755

Therapeutic advances in MicroRNA targeting.

Rusty L Montgomery1, Eva van Rooij.   

Abstract

In the last 10 years it has become increasingly clear that a large class of small noncoding RNAs, known as microRNAs (miRNAs) are potent and crucial regulators of important cellular processes such as differentiation, growth, and survival. miRNAs regulate gene expression through binding to 3' UTRs of target messenger RNAs whereby inducing either messenger RNA degradation or inhibition of protein translation. Although we have only just begun to gain some insight into the biology surrounding miRNAs, their apparent relevance and potency during the onset and progression of disease has generated a lot of interest in assessing the feasibility of therapeutic regulation of miRNAs. As a result of the short RNA nature of miRNAs and lessons learned from small interfering RNA therapeutics and gene therapy, within a timespan of a few years, incredible progress has been made in advancing miRNA regulation into the clinic. We summarize the various therapeutic tools that are currently being investigated to manipulate miRNAs with a special focus on cardiovascular disease and speculate on the future developments of miRNA therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20729755     DOI: 10.1097/FJC.0b013e3181f603d0

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  20 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

3.  miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A.

Authors:  Yin Ren; Ruanzhong Bao; Zhujun Guo; Jin Kai; Chen-Ge Cai; Zhu Li
Journal:  Exp Ther Med       Date:  2020-11-23       Impact factor: 2.447

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 5.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 6.  MiR-146a/b: a family with shared seeds and different roots.

Authors:  Mark R Paterson; Alison J Kriegel
Journal:  Physiol Genomics       Date:  2017-02-17       Impact factor: 3.107

Review 7.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

8.  MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician.

Authors:  Richard C Jin; Pil-Ki Min; Stephen Y Chan
Journal:  J Korean Soc Hypertens       Date:  2013-03-31

9.  Interfering nanoparticles for silencing microRNAs.

Authors:  Huricha Baigude; Tariq M Rana
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 10.  Can exercise teach us how to treat heart disease?

Authors:  Nina Mann; Anthony Rosenzweig
Journal:  Circulation       Date:  2012-11-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.